In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
As of close of business last night, Ascendis Pharma A/S ADR’s stock clocked out at $199.8, down -1.49% from its previous closing price of $202.82. In other words, the price has decreased by -$1.49 from its previous closing price. On the day, 0.79 million shares were traded. ASND stock price reached its highest trading level at $204.55 during the session, while it also had its lowest trading level at $198.02.
Ratios:
To gain a deeper understanding of ASND’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.73 and its Current Ratio is at 1.03.
Upgrades & Downgrades
In the most recent recommendation for this company, Wolfe Research on November 18, 2025, initiated with a Peer Perform rating and assigned the stock a target price of $255.
On October 17, 2025, Raymond James started tracking the stock assigning a Strong Buy rating and target price of $271.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 04 ’25 when JENSEN MICHAEL WOLFF bought 10,000 shares for $208.10 per share.
Jan Moller Mikkelsen bought 100,000 shares of ASND for $21,085,000 on Dec 02 ’25. On Dec 02 ’25, another insider, SPROGOE KENNETT, who serves as the Officer of the company, bought 10,000 shares for $209.32 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ASND now has a Market Capitalization of 12207412224 and an Enterprise Value of 12481969152. For the stock, the TTM Price-to-Sale (P/S) ratio is 16.94. Its current Enterprise Value per Revenue stands at 19.306 whereas that against EBITDA is -93.352.
Stock Price History:
The Beta on a monthly basis for ASND is 0.46, which has changed by 0.4871682 over the last 52 weeks, in comparison to a change of 0.13329959 over the same period for the S&P500. Over the past 52 weeks, ASND has reached a high of $229.94, while it has fallen to a 52-week low of $118.03. The 50-Day Moving Average of the stock is -3.05%, while the 200-Day Moving Average is calculated to be 9.78%.
Shares Statistics:
It appears that ASND traded 563.65K shares on average per day over the past three months and 879350 shares per day over the past ten days. A total of 61.10M shares are outstanding, with a floating share count of 60.47M. Insiders hold about 1.03% of the company’s shares, while institutions hold 104.72% stake in the company. Shares short for ASND as of 1764288000 were 3296433 with a Short Ratio of 5.85, compared to 1761868800 on 3549505. Therefore, it implies a Short% of Shares Outstanding of 3296433 and a Short% of Float of 6.47.
Earnings Estimates
Its stock is currently analyzed by 11.0 different market analysts. The consensus estimate for the next quarter is $0.41, with high estimates of $0.83 and low estimates of -$0.18.
Analysts are recommending an EPS of between -$1.78 and -$5.83 for the fiscal current year, implying an average EPS of -$3.21. EPS for the following year is $3.35, with 13.0 analysts recommending between $6.08 and $1.23.
Revenue Estimates
In. The current quarter, 11 analysts expect revenue to total $245.64M. It ranges from a high estimate of $257.9M to a low estimate of $225.58M. As of. The current estimate, Ascendis Pharma A/S ADR’s year-ago sales were $173.92MFor the next quarter, 11 analysts are estimating revenue of $276.31M. There is a high estimate of $298.9M for the next quarter, whereas the lowest estimate is $239.04M.
A total of 13 analysts have provided revenue estimates for ASND’s current fiscal year. The highest revenue estimate was $730.6M, while the lowest revenue estimate was $682.5M, resulting in an average revenue estimate of $714.87M. In the same quarter a year ago, actual revenue was $363.64MBased on 12 analysts’ estimates, the company’s revenue will be $1.29B in the next fiscal year. The high estimate is $1.44B and the low estimate is $1.11B.
